Presentations


Xbrane Company Presentation May 2023

Xbrane Company Presentation

Press Releases

08 Sep 2023

Xbrane announces that members of Xbrane’s management team have sold shares for tax purposes.

29 Aug 2023

Xbrane Biopharma releases interim report for January – June 2023

29 Aug 2023

XBRANE UPDATES AMBITION TO GENERATE POSITIVE OPERATING CASH FLOW ON AN MONTHLY BASIS BEFORE END OF FIRST QUARTER 2025

25 Aug 2023

Invitation to presentation of Xbrane Biopharma’s interim report January – June 2023 on August 29, 2023

25 Jul 2023

Xbrane invites to a webcast today Tuesday, July 25th, 2023

25 Jul 2023

STADA and Xbrane weigh options for ranibizumab biosimilar candidate

21 Jun 2023

Xbrane announce U.S. FDA filing acceptance for a Lucentis® (ranibizumab) biosimilar candidate

15 Jun 2023

Xbrane strengthens its commitment to sustainable business by joining the United Nations Global Compact

31 May 2023

Xbrane Biopharma releases interim report for January – March 2023

Financial Reports

29 Aug 2023

Interim Report January – June 2023

31 May 2023

Interim Report January – March 2023

31 Dec 2022

Annual report 2022

31 Dec 2022

Year-end report 2022

28 Oct 2022

Interim report January – September 2022

Financial Calendar

02 May 2024

Annual General Meeting

27 Mar 2024

Annual report 2023

29 Feb 2024

Year-end report 2023

30 Nov 2023

Interim report January – September 2023

Contact Investor Relations

Anette Lindqvist, CFO & Head of Investor Relation

Presentations and media


PRESENTATION AT PARETO HELTHCARE CONFERENCE

September 3, 2020

Presentation at LSX Nordic Congress

August 29, 2019

Presentation at BioStock Live

March 20, 2019